Literature DB >> 28598582

Outcomes of Intercalary Prosthetic Reconstruction for Pathological Diaphyseal Femoral Fractures Secondary to Metastatic Tumors.

Hong-Chao Huang1,2, Yong-Cheng Hu2, Deng-Xing Lun3, Jun Miao4, Feng Wang1, Xiong-Gang Yang1, Xin-Long Ma5.   

Abstract

OBJECTIVE: To evaluate the clinical outcomes and complications of segmental prosthetic reconstruction for pathological diaphyseal femoral fractures secondary to metastatic tumors.
METHODS: Between 2011 and 2015, we retrospectively evaluated 16 patients (6 men and 10 women; 64.5 ± 11.4 years old at diagnosis) who underwent prosthetic reconstruction after segmental resection of diaphyseal femoral fractures due to metastatic lesions. Visual analog scale (VAS), functional outcomes, implant-related complications, and Mean postoperative Musculoskeletal Tumor Society (MSTS) score for each patient were collected.
RESULTS: The mean length of bone defect was 10.2 ± 2.6 cm (range, 8-16 cm); follow-up was 9 ± 6.8 months (range, 2-25 months) for all patients, and 24 months (23 and 25 months) for the 2 patients still alive. At final follow-up, 14 patients were dead, indicating a mean survival of 6.9 ± 3.6 months (range, 2-14 months). Mean preoperative VAS score was 8.5 ± 1.0, which decreased to 2.5 ± 1.3 at day 2 postoperatively, indicating significant pain relief (P < 0.05). The MSTS score for lower extremities was 84.6% (range, 73%-90%). The range of motion and function of adjacent joints was within the normal limits in all cases. Three patients (33%) developed complications, including aseptic loosening because of disease progression (1), infection (1), and peri-prosthesis fracture (1).
CONCLUSION: These findings demonstrated that this approach greatly relieves pain, and yields satisfactory functional outcomes with fewer complications in patients with pathological femoral fractures secondary to metastatic tumors; however, survival was not significantly improved.
© 2017 Chinese Orthopaedic Association and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  Diaphyseal femoral fracture; Functional outcome; Intercalary prostheses; Metastatic tumors

Mesh:

Year:  2017        PMID: 28598582      PMCID: PMC6584426          DOI: 10.1111/os.12327

Source DB:  PubMed          Journal:  Orthop Surg        ISSN: 1757-7853            Impact factor:   2.071


  34 in total

1.  Biomechanical analysis of humeral diaphyseal segmental defect fixation.

Authors:  Jon C Henry; Timothy A Damron; Marsha M Weiner; Michael E Higgins; Fred W Werner; Franklin H Sim
Journal:  Clin Orthop Relat Res       Date:  2002-03       Impact factor: 4.176

2.  Case report: Reconstruction of an intercalary defect with bone transport after resection of Ewing's sarcoma.

Authors:  John P Dormans; Onder Ofluoglu; Bulent Erol; Leslie Moroz; Richard S Davidson
Journal:  Clin Orthop Relat Res       Date:  2005-05       Impact factor: 4.176

3.  Does the second-generation intercalary humeral spacer improve on the first?

Authors:  Timothy A Damron; Taninnit Leerapun; Ronald R Hugate; Thomas C Shives; Franklin H Sim
Journal:  Clin Orthop Relat Res       Date:  2008-04-18       Impact factor: 4.176

4.  Endoprosthetic replacement of diaphyseal bone defects. Long-term results.

Authors:  E Aldlyami; A Abudu; R J Grimer; S R Carter; R M Tillman
Journal:  Int Orthop       Date:  2005-01-05       Impact factor: 3.075

5.  Metastatic lesions of the humerus treated with the isoelastic diaphysis prosthesis.

Authors:  M Schürmann; G Gradl; H J Andress; T Kauschke; H Hertlein; G Lob
Journal:  Clin Orthop Relat Res       Date:  2000-11       Impact factor: 4.176

6.  Prognostic factors and a scoring system for patients with skeletal metastasis.

Authors:  H Katagiri; M Takahashi; K Wakai; H Sugiura; T Kataoka; K Nakanishi
Journal:  J Bone Joint Surg Br       Date:  2005-05

7.  Intercalary endoprosthetic reconstruction for diaphyseal bone tumours.

Authors:  E R Ahlmann; L R Menendez
Journal:  J Bone Joint Surg Br       Date:  2006-11

8.  Minimally invasive treatment of pathological fractures of the humeral shaft.

Authors:  Onder Ofluoglu; Bulent Erol; Zerrin Ozgen; Muzaffer Yildiz
Journal:  Int Orthop       Date:  2008-04-03       Impact factor: 3.075

9.  Adamantinoma of the tibia treated with a new intramedullary diaphyseal segmental defect implant.

Authors:  A F Mavrogenis; V I Sakellariou; H Tsibidakis; P J Papagelopoulos
Journal:  J Int Med Res       Date:  2009 Jul-Aug       Impact factor: 1.671

10.  SECONDARY MALIGNANT DISEASE OF BONE.

Authors:  A CLAIN
Journal:  Br J Cancer       Date:  1965-03       Impact factor: 7.640

View more
  5 in total

1.  Union, complication, reintervention and failure rates of surgical techniques for large diaphyseal defects: a systematic review and meta-analysis.

Authors:  Pietro Feltri; Luca Solaro; Alessandro Di Martino; Christian Candrian; Costantino Errani; Giuseppe Filardo
Journal:  Sci Rep       Date:  2022-06-01       Impact factor: 4.996

2.  En bloc resection and intercalary prosthesis implantation for the treatment of humeral diaphyseal bone metastases.

Authors:  Feifei Pu; Zhicai Zhang; Baichuan Wang; Jianxiang Liu; Zengwu Shao
Journal:  Int Orthop       Date:  2020-10-06       Impact factor: 3.075

3.  New 3-dimensional implant application as an alternative to allograft in limb salvage surgery: a technical note on 10 cases.

Authors:  Jong Woong Park; Hyun Guy Kang
Journal:  Acta Orthop       Date:  2020-07-03       Impact factor: 3.717

4.  Preliminary results of a new intercalary modular endoprosthesis for the management of diaphyseal bone metastases.

Authors:  Kadir Büyükdoğan; Barlas Göker; Mazhar Tokgözoğlu; Ulukan İnan; Korhan Özkan; Tahsin Sami Çolak; Lercan Aslan; Mehmet Ali Deveci; Mehmet Ayvaz
Journal:  Jt Dis Relat Surg       Date:  2021-11-19

5.  Is three-dimensional-printed custom-made ultra-short stem with a porous structure an acceptable reconstructive alternative in peri-knee metaphysis for the tumorous bone defect?

Authors:  Jie Wang; Jingjing An; Li Min; Chongqi Tu; Minxun Lu; Yuqi Zhang; Jingqi Lin; Yi Luo; Yong Zhou
Journal:  World J Surg Oncol       Date:  2021-08-08       Impact factor: 2.754

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.